HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 37, 38820-38829, September 10, 2004

This Article Abstract Full Text (PDF) All Versions of this Article: 279/37/38820    most recent M401663200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Y. Articles by Wu, M. Search for Related Content PubMed PubMed Citation Articles by Yang, Y. Articles by Wu, M. Social Bookmarking                      What's this?

Nucleocytoplasmic Shuttling of Receptor-interacting Protein 3 (RIP3)

IDENTIFICATION OF NOVEL NUCLEAR EXPORT AND IMPORT SIGNALS IN RIP3^*

Yonghui Yang, Jun Ma, Youjun Chen, and Mian Wu¶

From the Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026, People's Republic of China and the School of Biological Sciences, Nanyang Technological University, 60 Nanyang Dr., Singapore 637551

Received for publication, February 15, 2004 , and in revised form, June 17, 2004.

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Receptor-interacting protein 3 (RIP3), a member of the RIP Ser/Thr kinase family, has been characterized as a pro-apoptotic protein involved in the tumor necrosis factor receptor-1 signaling pathway. In this study, we have mapped a minimal region of RIP3 sufficient for apoptosis induction to a fragment of 31 amino acids in length. This minimal region also functions as an unconventional nuclear localization signal sufficient to confer the import of full-length RIP3 to the nucleus to trigger apoptosis, suggesting that RIP3 is able to play an apoptosis-inducing role in the nucleus. In addition, we have characterized two novel leucine-rich nuclear export signals (NESs) that are responsible for the nuclear export of RIP3 to the cytoplasm via a chromosome region maintenance 1 (CRM1)-dependent pathway and an extra leucine-rich NES in the N terminus of RIP3 that contributes to the cytoplasmic distribution in a CRM1-independent manner. Thus, we provide the first evidence that RIP3 acts a nucleocytoplasmic shuttling protein, which presents a possible link between death receptor signaling and nuclear apoptosis.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The receptor-interacting protein (RIP)¹ Ser/Thr kinase family consists of four members, including RIP, RIP2 (RICK/CARDIAK), RIP3, and RIP4 (DIK/PKK) (1-4). RIP3 is an important component of the tumor necrosis factor receptor-1 (TNFR1) signaling complex. Sequence analysis reveals that RIP3 contains an N-terminal RIP-like kinase domain (amino acids 21-287) that shares extensive homology with the corresponding N-terminal kinase domain in other RIP family members. Interestingly, in sharp contrast to RIP, which has a C-terminal death domain (DD), RIP2, which has a C-terminal caspase-recruiting domain, and RIP4, which has 11 C-terminal ankyrin repeats, RIP3 possesses a unique C-terminal domain (amino acids 288-518) that shares no significant homology to any known proteins.

It has been shown that the N terminus of RIP3 is required for its kinase activity and autophosphorylation, whereas the C terminus of RIP3 is responsible for caspase activation and apoptosis induction (1-3, 5). Furthermore, RIP3 is recruited to the TNFR1 signaling complex through interaction with RIP via its C-terminal segment, and, once recruited to the complex, RIP3 could exert a pro-apoptotic activity that may be partially accomplished by activating caspases and/or by inhibiting RIP- and TNFR1-induced NF-B activation (2, 6). Although RIP3 is involved in TNF--mediated apoptosis, the mechanism by which RIP3 induces cell death remains largely unclear (7). Because the C terminus of RIP3 is unique and involved in apoptosis induction, we are mainly focused on this unique C-terminal segment to investigate its functional significance in RIP3 signaling.

Previous studies have demonstrated that both TNF receptor-associated death domain (TRADD) and Fas-associated death domain (FADD), two essential DD-containing adapter molecules, are recruited to the TNFR1 complex during TNF--induced death signaling, and their function and localization are widely assumed to be cytoplasmic. However, recent studies have shown that TRADD and FADD contain both a nuclear export signal (NES) and a nuclear localization signal (NLS), capable of nuclear export and import and causing proteins to transport between the cytoplasm and the nucleus (8-10). Moreover, TRADD and FADD also appear to have apoptotic activity in the nucleus. The detailed mechanisms of nucleocytoplasmic transport and possible roles of these proteins in nuclear apoptotic signaling remain unclear.

In this study, we have delineated a minimal domain of RIP3 sufficient for apoptosis induction to amino acids (aa) 442-472, a short region of 31 residues in length. This fragment (aa 442-472) also functions as an unconventional NLS and is found to be located predominantly in the nucleus. Furthermore, we present the evidence that RIP3 is a nucleocytoplasmic shuttling protein. This characterized single NLS is capable of conferring the import of full-length RIP3 protein to the nucleus. In addition, we identified two novel leucine-rich NESs that are responsible for the nuclear export of RIP3 via a CRM1-mediated mechanism and an additional leucine-rich NES in the N-terminal region of RIP3, which appears to regulate the cytoplasmic distribution of RIP3 in a CRM1-independent manner.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Reagents—Hoechst 33342 and general caspase inhibitor Z-VAD-Fmk were purchased from Sigma. MitoTracker Red CMXRos was obtained from Molecular Probes. NES inhibitor leptomycin B (LMB) was a generous gift from Dr. Minoru Yoshida (RIKEN Institute, Japan).

Plasmid Construction—The cDNA encoding full-length RIP3 was isolated by PCR from human brain cDNA library (Clontech). The amplified fragment was digested with BglII and XhoI and then cloned into BglII-XhoI sites of pEGFP-C1 (Clontech) to generate pEGFP-C1/RIP3. The EcoRI- and XhoI-digested segment coding for the truncated mutant RIP3N223 was inserted into EcoRI-SalI-digested pEGFP-C1 to yield pEGFP-C1/RIP3N223. The fragment coding for RIP3 was digested with SalI and NotI and subcloned into the compatible sites of pCI-neo/Myc to create pCI-neo/Myc-RIP3. Various N-terminally GFP-tagged RIP3 mutants used for mapping the minimal region and attesting both NESs and NLSs were created by inserting EcoRI-XhoI-digested fragments into EcoRI-SalI sites of pEGFP-C1. The fragments coding for Bcl-ramboN204 or amino acid residues 1-56 from Smac/DIABLO were digested and inserted into EcoRI-SalI sites of pEGFP-C1 or BglII-XhoI sites of pEGFP-N1 (Clontech), respectively. The BamHI-NotI-digested fragment encoding GFP-RIP3N223 or GFP-RIP3 was subcloned into the same sites of pHis-TAT-PTD-GFP (11) to create pHis-TAT-PTDGFP-RIP3N223 or pHis-TAT-PTD-GFP-RIP3. All the primers used in this study and construction details are available on request.

Cell Culture and Transfection—HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37 °C in 5% CO₂. Transfections of cells were performed using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's specifications.

Apoptosis Assays—Apoptosis assays were performed mainly as described previously (12) with a slight modification. HeLa cells in 24-well plates were cultured to subconfluence (5 x 10⁵ cells) and transiently transfected with the indicated plasmids. At 24 h post-transfection, both floating and adherent cells were fixed and stained with 2 µg/ml Hoechst 33342. At least eight different fields were selected randomly, and the percentages of apoptotic cells among the total number of cells were counted based on the dead cells having DNA fragmentation and/or chromatin condensation under a fluorescence microscope and morphological changes under phase contrast. The data are the means of at least three independent experiments.

Western Blotting—Western blot was carried out as described by Yang et al. (11). Briefly, cells were harvested, washed, and then resuspended in lysis buffer (50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.5% Nonidet P-40) supplemented with protease inhibitor mixture (Roche Applied Science) on ice for 30 min. The lysates were centrifuged, and both supernatants and pellets were mixed with an equal volume of 2x Laemmli buffer, respectively. The samples were separated by 12% SDS-polyacrylamide gel, and the resolved proteins were transferred onto a nitrocellulose membrane (Amersham Biosciences). The blot was blocked with 5% milk in Tris-buffered saline plus Tween (TBST) and then incubated with mouse anti-GFP polyclonal antibody (Clontech) for 1 h at room temperature. After washing three times with TBST, the membrane was incubated with alkaline phosphatase-conjugated goat anti-mouse immunoglobulin (Promega). The membrane was washed three times with TBST followed by two brief washes with TBS. The proteins were visualized using Western Blue-stabilized substrate for alkaline phosphatase (Promega).

Site-directed Mutagenesis—PCR-based site-directed mutagenesis was performed mainly as described previously (13). All the mutations induced by PCR were further verified by DNA sequencing.

Indirect Immunofluorescence—HeLa cells were grown on glass coverslips and then transiently transfected with the indicated plasmids. At 24 h after transfection, cells were washed once with PBS, fixed with 4% paraformaldehyde, permeabilized with 0.05% Triton X-100 in PBS, and then blocked with 3% bovine serum albumin in PBS for 30 min. The cells were incubated with mouse anti-Myc monoclonal antibody (1:500, Clontech) for 1 h at room temperature, followed by rhodamine-conjugated goat anti-mouse secondary antibody (1:200, Jackson ImmunoResearch Laboratories) for another 1 h. After rinsing three times with PBS for 5 min, the cells were stained with 1 µg/ml Hoechst 33342 for 1 min, mounting medium containing an anti-fading agent (Vector Laboratories) was added, and the cells were visualized under a fluorescence microscope using standard filter for red fluorescence. Images were captured with an Olympus IX70 microscope controlled by Viewfinder Lite (version 1.0) armed with a x40 objective lens.

Computational Amino Acid Sequence Analysis—Multiple sequence alignments were performed using Multalin software (14).

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Mapping the Minimal Region of RIP3 Sufficient for Apoptosis Induction—Previous studies have shown that expression of RIP3 induces apoptosis, but the minimal domain of RIP3 that promotes apoptosis remains uncharacterized. To pinpoint the minimal region of RIP3 that is sufficient to induce cell death, we prepared a series of constructs by linking GFP to the N terminus of RIP3 deletion mutants (Fig. 1A). The expression of all the GFP fusion constructs was verified by Western blot (Fig. 1B). As shown in Fig. 1 (A and C), unlike RIP3N223, which was shown to promote cell death (2), RIP3-(224-460) lacking the C-terminal 58 residues failed to induce apoptosis, indicating that aa 461-518 were required for its pro-apoptotic activity. However, RIP3N460 was found unable to mediate apoptosis, suggesting that the region spanning residue 460 appeared to be crucial for its apoptotic function. As shown in Fig. 1 (A and C), besides RIP3N350 and RIP3N428, a smaller fragment RIP3-(429-483) with only 55 residues in length was also able to induce apoptosis spontaneously.

View larger version (37K): [in this window] [in a new window]   FIG. 1. Mapping a minimal region in RIP3 for its apoptosis induction. A, schematic representation of the different N-terminally GFP-tagged RIP3 deletion constructs. B, HeLa cells were transiently transfected with 0.5 µg of pEGFP-C1 control vector or the indicated constructs. 24 h after transfection, cells were harvested and lysed, and protein expression was confirmed by Western blot using anti-GFP antibody. C, HeLa cells were transiently transfected with 0.5 µg of pEGFP-C1 empty vector or the indicated constructs. At 24 h post-transfection, cells were counted for ratio of apoptotic cells as described under "Experimental Procedures."

RIP3 Is Localized to the Cytoplasm, but Not to Mitochondria—Cellular compartmentation is essential for proper function of a protein. RIP3 is recruited to the TNFR1 complex and is thus assumed to be primarily cytoplasmic. However, the precise subcellular localization of RIP3 from limited published data remains controversial (5, 6). To ascertain the intracellular localization of RIP3 in living cells, GFP, GFP-tagged RIP3, or GFP-tagged RIP3N223 was transfected into HeLa cells, respectively (Fig. 2A). The expression of constructs was confirmed by Western blotting (Fig. 2B). As shown in Fig. 2C, GFP alone was distributed evenly throughout the cells (panel a). In contrast, the full-length RIP3 fused to the C terminus of GFP was located specifically in the cytoplasm in a diffused pattern (panel e). Similarly, fusion of RIP3N223 with GFP also displayed a cytoplasmic localization, but predominantly in a punctuated pattern within the cytoplasm (panel i). To examine whether these two different cytoplasmic localization patterns resulted from both full-length RIP3 and the N-terminal-truncated RIP3N223 could be attributed to the kinase activity in the N terminus of RIP3, we generated a point mutant RIP3 (K50A), in which Lys⁵⁰ was replaced by alanine to abrogate the kinase activity of RIP3 (1, 2). As shown in Fig. 2C, the K50A substitution significantly increased the number of cells with punctate structures within the cytoplasm (panel m), indicating that the loss of kinase activity may associate with the accumulation of punctate structures within the cytoplasm. It is worthwhile to point out that our conclusion regarding cytoplasmic localization of RIP3 differed from a previous report in which they claimed that RIP3 was solely localized to the mitochondrion (5). To have a sustainable support for our conclusion, we further utilized two bona fide mitochondrial proteins, namely Bcl-rambo and Smac/DIABLO (15, 16), as references for mitochondrial location. As shown in Fig. 2 (A and C), GFP fusion protein, with truncated Bcl-rambo (Bcl-ramboN204) containing its C-terminal membrane anchor, was found exclusively in the mitochondrion (Fig. 2C, panel q). Likewise, when a segment consisting of the first 56 residues (mitochondrial targeting sequence (MTS)) from Smac/DIABLO was fused to the N terminus of GFP (Fig. 2A), this GFP fusion protein was specifically distributed in mitochondria (Fig. 2C, panel u). As expected, the merged images for both GFP-Bcl-ramboN204 and sMTS/56-GFP showed a uniform yellow pattern (Fig. 2C, panels t and x). In contrast, merged images shown in Fig. 2C (panels h, l, and p) revealed that RIP3, RIP3N223, and RIP3 (K50A) localizations were quite distinct from the mitochondrial localizations specified by MitoTracker Red. Taken together, we clearly demonstrated that both full-length RIP3 and RIP3N223 were mainly localized to the cytoplasm, but not to mitochondria.

View larger version (49K): [in this window] [in a new window]   FIG. 2. Subcellular localization of RIP3. A, schematic illustration of the different GFP-tagged expression constructs. The K50A substitution is indicated by an asterisk. B, HeLa cells were transiently transfected with GFP control, GFP-tagged RIP3N223, RIP3, RIP3 (K50A), BclramboN204, or sMTS/56. After 24 h, cells were harvested and subjected to Western blot analysis using anti-GFP antibody. C, HeLa cells were transiently transfected with the indicated constructs. For RIP3, RIP3 (K50A), and RIP3N223, transfected cells were incubated with the general caspase inhibitor Z-VAD-Fmk (40 µM) to prevent cell death. At 24 h post-transfection, cells were stained with MitoTracker Red (20 nM) and Hoechst 33342 (2 µg/ml) for 5 min at 37 °C and then viewed by fluorescence microscopy (magnification x400). Micrographs showed GFP fluorescence (green, panels a, e, i, m, q, and u), MitoTracker (red, panels b, f, j, n, r, and v), and Hoechst (blue, panels c, g, k, o, s, and w) staining; merged images (panels d, h, l, p, t, and x) were a composite of the three panels performed using Adobe Photoshop 6.0.

View larger version (46K): [in this window] [in a new window]   FIG. 3. Nucleocytoplasmic shuttling of RIP3. A, HeLa cells were transiently transfected with GFP-tagged RIP3 (left and middle panels) or YFP3 (right panel). 24 h after transfection, cells were left untreated (first row) or treated (second row) with LMB (2 ng/ml) for 1 h at 37 °C or 4 °C, and cellular localization was examined by fluorescence microscopy (magnification x400). B, myc-tagged RIP3 was transiently transfected into HeLa cells. After 24 h, cells were left untreated (upper panel) or treated (lower panel) with LMB (2 ng/ml) at 37 °C for 1 h. Cells were fixed, probed with anti-Myc antibody, followed by rhodamine-conjugated goat anti-mouse secondary antibody, counter-stained with Hoechst 33342, and visualized under phase contrast or fluorescence microscope (magnification x400). Arrows indicate the nuclei of cells expressing Myc-RIP3. C, HeLa cells expressing TAT-PTD-GFP-RIP3 were examined by fluorescence microscopy (magnification x400).

In addition, a construct coding for a chimeric fusion protein containing an exogenous NLS from HIV-1 TAT protein transduction domain (PTD) (11) at the N terminus of GFP-RIP3 was transiently transfected into HeLa cells (Fig. 3C). Unexpectedly, TAT-PTD-GFP-RIP3 was found to localize mainly in the cytoplasm instead of being targeted into the nucleus by TAT-PTD, indicating that the nuclear export activity of RIP3 may have overcome the nuclear targeting ability of TAT-PTD, resulting in a net export of TAT-PTD-GFP-RIP3 from the nucleus.

Identification and Characterization of Two Functional Leucine-rich NESs in RIP3—We have shown that RIP3N223 was located to the cytoplasm and promoted apoptosis. To investigate whether the cytoplasmic location of RIP3N223 is necessary for its apoptotic activity, we once linked a TAT-PTD (NLS) to RIP3N223 to change its subcellular location from the cytoplasm to the nucleus. To our surprise, TAT-PTD (NLS), when fused to the N terminus of GFP-RIP3N223, failed to dislocate the TAT-PTD-GFP-RIP3N223 into the nucleus (Fig. 4A), implying that a cytoplasmic retention sequence or NES may exist in this region. To address this point, we scrutinized the amino acid sequence in this region and found two distinctive leucine-rich NES-like sequences, one is ²⁵⁵LEGLKELMQL²⁶⁴ (NES-1) near the C terminus of the kinase domain, and the other is ³⁴⁴MVSEWLNKLNL³⁵⁴ (NES-2) present at the unique C terminus of RIP3 (Fig. 4B). These sequences resembled those previously identified leucine-rich NESs characterized by the presence of four closely spaced hydrophobic residues, most often leucine (17). Sequence alignments revealed that two NES-like motifs of RIP3 were closely similar to the NES consensus (Fig. 4C).

View larger version (92K): [in this window] [in a new window]   FIG. 4. RIP3 contains two putative leucine-rich NESs. A, HeLa cells were transiently transfected with pHis-TAT-PTD-GFP or pHis-TATPTD-GFP-RIP3N223 (in the presence of Z-VAD-Fmk). At 24 h, the subcellular localization was observed under fluorescence microscope (magnification, x400). B, schematic representation of the primary structure of RIP3 showing the various protein domains as described by Yu et al. (1), Sun et al. (2), and this study. Arrows indicate two NESs identified in this study. Numbers refer to the positions of the amino acids in RIP3. Conserved residues are shown in bold. C, multiple amino acid sequence alignments of the NESs in RIP3 with other previously characterized NESs in human proteins. Dark shading indicates identical or similar residues in the NESs. The underlined amino acids in the NESs of RIP3 represent the substitutions of conserved residues to alanine. D, schematic diagram of the different N-terminally GFP-tagged RIP3 deletion mutants. Two putative NESs and their positions are indicated. N, nuclear; C, cytoplasmic; N+C, both nuclear and cytoplasmic. HeLa cells were transiently transfected with the indicated constructs, including deletion mutants and point mutants. 24 h after transfection, subcellular distribution was viewed in living cells by fluorescence microscopy (magnification, x400), and expression was analyzed by Western blot with anti-GFP antibody. E, HeLa cells expressing GFP-tagged RIP3-(224-287) or RIP3-(288-358) were left untreated or treated with LMB (2 ng/ml) at 37 °C for 1 h, cells were stained with Hoechst, and cellular localization was visualized by fluorescence microscopy (magnification, x400). F, 24 h after transient transfection, HeLa ells expressing GFP-RIP3-(288-358) were left untreated or treated with LMB (2 ng/ml) for the indicated periods of time. At specific time points, cells were stained with Hoechst and then visualized directly in living cells under a fluorescence microscope (magnification, x400).

It has been shown that the leucine residues within the leucine-rich NES are critical for its nuclear export activity (18). To elucidate the functional significance of these hydrophobic residues, we generated two point mutants in which leucine was substituted to alanine (Fig. 4C). As shown in Fig. 4D, mutant RIP3-(224-287) L255A/L258A/L261A/L264A (NES-1m) dramatically disrupted the cytoplasmic localization and distributed throughout the cells. Likewise, mutant RIP3-(288-358) M344A/L349A/L352A/L354A (NES-2m) was found in both the nucleus and cytoplasm. We therefore concluded that RIP3 owns two functional NES-1 and NES-2, and mutations at mostly conserved residues (Leu or Met) within NESs completely abolish their nuclear export activity and thus result in relocation to both the nucleus and cytoplasm.

Protein export from the nucleus is often mediated by the leucine-rich NES that interacts with its export receptor CRM1, which is specifically inhibited by LMB (19, 20). To test whether these two NESs are sensitive to LMB, we examined the effect of LMB treatment on NES-1 and NES-2. As shown in Fig. 4E, both RIP3-(224-287) and RIP3-(288-358) were sensitive to LMB treatment and resulted in nuclear accumulation by passive diffusion because of their small size, confirming that both NES-1 and NES-2 are capable of directing proteins from the nucleus to the cytoplasm in an LMB-sensitive, CRM1-dependent nuclear export manner.

In addition, the time course of LMB treatment on the nuclear export activity of NES-2 was also examined. Cells expressing RIP3-(288-358) were incubated with LMB at 37 °C for the indicated periods of time and further examined by fluorescence microscopy. As seen in Fig. 4F, RIP3-(288-358) rapidly entered the nucleus as early as 5 min after LMB treatment, and an increasing nuclear accumulation was observed as incubation time proceeded.

Identification of an LMB-insensitive NES in the N Terminus of RIP3—To further investigate whether there exits additional NESs in the N-terminal region of RIP3 that may regulate the cytoplasmic distribution, we examined carefully the RIP3 primary sequence ranging from aa 1 to 223. Three presumed leucine-rich NES-like sequences were categorized, and interestingly, one of which (NES-3) was shown to contain two overlapping NES-like motifs I and II (Table I). To determine whether these NES-like sequences are functional, each putative NES-like motif was fused to GFP and their subcellular distributions were then examined under a fluorescence microscope. As shown in Fig. 5A, RIP3-(143-173), RIP3-(174-223), or RIP3-(143-223), respectively, containing NES-4, NES-5, or both was found unable to export GFP to the cytosol, demonstrating that neither NES-4 nor NES-5 was functional. In contrast, RIP3-(1-223), RIP3-(1-142), or RIP3-(104-142), each of which contains NES-3, showed a considerable cytosolic distribution, implying that the short leucine-rich sequence NES-3 is functional and sufficient to export GFP protein to the cytoplasm.

View larger version (37K): [in this window] [in a new window]   FIG. 5. The N-terminal region of RIP3 contains a novel LMB-insensitive NES. A, schematic representation of three putative NESs at the N terminus of RIP3 and the intracellular localization of N-terminally GFP-tagged RIP3 truncations. C, cytoplasmic; N+C, both nuclear and cytoplasmic; ND, not determined. HeLa cells were transiently transfected with the indicated deletion constructs. 24 h after transfection, expression was confirmed by Western blot with anti-GFP antibody, and cellular distribution was examined in living cells by fluorescence microscopy (magnification, x400). B, HeLa cells expressing GFP-tagged RIP3-(1-223), RIP3-(1-142), or RIP3-(104-142) were left untreated (upper) or treated (lower) with LMB (2 ng/ml) at 37 °C for 1 h, and cellular localization was visualized under a fluorescence microscope (magnification, x400).

RIP3 Contains a Putative Nuclear Localization Signal—Mutant RIP3N350, which lacks NES-1, NES-3, and part of NES-2, was found to accumulate mainly in the nucleus, which strongly prompted us to hypothesize that a potential NLS might be present in this region. After careful inspection, we deduced three discernible NLS-like sequences in the aa 224-518 region (Fig. 6A), however, these underlined NLS-like motifs were eventually demonstrated to be nonfunctional (data not shown).

View larger version (44K): [in this window] [in a new window]   FIG. 6. RIP3 possesses a novel NLS. A, amino acid sequence of RIP3N223. The determined NES1 and NES2 are boxed, three potential NLSs are underlined, and the putative "unconventional" NLS identified in this study are boxed and shaded. B, HeLa cells were transiently transfected with RIP3-(442-472) or RIP3-(451-472) construct in the presence of Z-VAD-Fmk (40 µM). After 24 h, cells were examined by fluorescence microscopy (magnification, x200). C, HeLa cells were transiently transfected with the indicated RIP3 constructs in the presence of Z-VAD-Fmk (40 µM). 24 h after transfection, the floating dead cells were removed and the numbers of cells showing nuclear, cytoplasmic, or nuclear and cytoplasmic localization in a total of six different fields were counted for each deletion mutant. D, schematic diagram showing the locations of NLS, wild type NES, and mutant NES in RIP3. The gray bar represents the kinase domain, and the open bar denotes the unique C-terminal domain. 24 h after transfection with the indicated mutant constructs in HeLa cells, expression was confirmed by Western blot with anti-GFP antibody, and relative cellular distribution was observed in living cells by fluorescence microscopy (magnification, x400).

To further clarify the role of this unique NLS in the context of full-length RIP3 protein, we first created a point mutant GFP-RIP3-NES-1m-2m, in which all conserved leucine residues in NES-1 and NES-2 were replaced by alanine to abolish the nuclear export activity (Fig. 6D). Following transient transfection in HeLa cells, GFP-RIP3-NES-1m-2m was found mainly in the cytoplasm, despite the finding that more fluorescence was observed in the nucleus than that of wild-type RIP3 (Figs. 6D and 2C, panel e), suggesting that the intact NES-3 may regulate the nuclear export of RIP3 and counteract the nuclear import by NLS. To confirm this premise, we further constructed two deletion mutants, namely GFP-RIP3-NES-1m-2mN142, which lacks the first 142 residues at its N terminus, and GFP-RIP3-NES-1m-2mNES-3, which is only missing NES-3 (Fig. 6D). As expected, both RIP3-NES-1m-2mN142 and RIP3-NES-1m-2mNES-3 were found to be localized in the nucleus with some noticeable dot-like structures in the cells (Fig. 6D), demonstrating that NLS is truly responsible for the nuclear import of full-length RIP3.

As described above, aa 442-472 functions not only as an NLS, but also as an apoptosis-inducing domain. Any the RIP3 deletion version, as long as it contains aa 442-472, was shown to induce apoptosis regardless of its nuclear or cytoplasmic localization (Table II). It is interesting to note that all RIP3 constructs exhibiting nuclear localization were found to promote cell death, suggesting that the apoptotic function of RIP3 may well correlate to the nucleus. This observation is supported by the recent data that TRADD and FADD were able to induce cell death in the nucleus (8-10).

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
In the present study, we have mapped an apoptosis-inducing domain of RIP3 to aa 442-472, a minimal region of 31 residues in length that alone is sufficient to trigger significant apoptosis in HeLa cells. We believe this peptide is of particularly importance, because it could potentially be developed as a therapeutic antitumor agent in pre-clinical research by virtue of its diffusible nature (3.5 kDa). The exact apoptotic effects of this peptide both in vitro and in vivo are currently being investigated. Moreover, we demonstrated that aa 442-472 confers both nuclear localization and apoptosis induction. The nuclear apoptotic function of RIP3 presented in this study is novel, because RIP3 has been considered for a long time to be cytosolic and its nuclear function has never been proposed previously.

Although the C terminus of RIP3 shares no significant homology to other RIP family members, limited similarities in certain regions can still be observed, which may explain, to some extent, the functional significance of this region for its apoptotic activity and the protein-binding ability of RIP3 (5). Interestingly, RIP3-(442-472) happens to contain the core 16 residues of RIP homotypic interaction motif (aa 451-466) that is necessary, but not sufficient, for interaction with RIP (6). Sun et al. (6) reported that aa 411-474 of RIP3 is the minimal region for its association with RIP, and if this was the case, the defined aa 442-472 would not be able to interact with RIP, implying that the apoptotic function of RIP3 may not have to rely on RIP-RIP3 interaction.

The subcellular localization studies of RIP3 have remained controversial based on the limited evidence from two groups (5, 6). In accordance with the observation from Sun et al. (6), we have shown that RIP3 is primarily localized in the cytoplasm, but not to mitochondria. Prediction of the RIP3-sorting sequence by PSORTII failed to disclose any recognizable mitochondrial targeting or anchor sequence within RIP3, which partially supports our conclusion that RIP3 is unlikely to localize to mitochondria. Although we have shown that the punctate structures accumulated in the cytoplasm appear to be closely related to the loss of RIP3 kinase activity, the possibility that some other cellular proteins prefer to associate with RIP3N223 to form punctate structures in the cytosol can not be excluded completely.

Leucine-rich NESs consist of four or five hydrophobic residues within a region that is 10 amino acids in length. The widely accepted NES consensus is LX_2,3[LIVFM]X_2,3LX[LI] (17). In this study, we have identified and characterized two novel leucine-rich NESs in RIP3, which are not only structurally similar to consensus, but also functionally active. NES-1 and NES-2 were shown to powerfully export proteins from the nucleus to the cytosol via an LMB-sensitive, CRM1-dependent pathway. Moreover, sequence alignments of human RIP3 with mouse RIP3 (mRIP3) (3) revealed two previously unidentified leucine-rich NES-like motifs in mRIP3, one is ²⁶⁰LEKLKELMI²⁶⁸, and the other is ³³⁹MVSKMLDRLHL³⁴⁹, which, respectively, correspond to NES-1 and NES-2 delineated in this study. These data suggest that leucine-rich NESs might be highly conserved in RIP3 across different species and further imply that they must have played indispensable roles during the evolution of RIP3 in determining cytoplasmic localization.

In addition to NES-1 and NES-2, we have discovered another novel leucine-rich NES-3 at the N terminus of RIP3, which is also involved in regulating nuclear export of RIP3. However, different from NES-1 and NES-2, the nuclear export activity of NES-3 was found to be LMB-insensitive, thus it functions as a CRM1-independent NES. This conclusion was further validated by a complementary observation that two novel splicing variants of RIP3, both retaining NES-3 but lacking NES-1, NES-2, and NLS, were found to be localized predominantly in the cytoplasm and insensitive to LMB treatment.² Similar to RIP3, -catenin was recently reported to contain a weak LMB-insensitive NES-1 and a strong LMB-sensitive NES-2, both involved in the nuclear export of -catenin via a CRM1-dependent pathway (21).

Although CRM1-mediated export remains the most extensively studied export pathway to date, other export receptors have been identified (17). Recently, calreticulin was shown to mediate export of protein kinase inhibitor in an NES-dependent, LMB-insensitive manner, indicating that CRM1 might not be the only export receptor recognizing the leucine-rich NES (22). Therefore, in the case of RIP3, more experiments are needed to investigate the detailed mechanism of how the nuclear export by NES-3 is achieved in a CRM1-independent fashion.

Entering the nucleus by GFP-tagged RIP3 can not be a form of passive diffusion, because its molecular size (80-90 kDa) is much bigger than the size limit (40-60 kDa) of nuclear pore complex (23) and this nuclear import is completely abolished at 4 °C. A cytoplasmic protein, YFP₃, with a comparable size (>80 kDa) but lacking any endogenous NLS, is incapable of entering the nucleus under similar conditions. These data indisputably demonstrate that the nuclear translocation of RIP3 is an active, temperature-dependent process.

The nuclear import of proteins involves the recognition of NLS by importins and/or , translocation through the nuclear pore complex, and release in the nucleus (24). The best characterized "classic" NLS consists of either one (monopartite) or two (bipartite) clusters of basic amino acid residues, predominately lysine or arginine. However, a variety of other sequences that bears no obvious resemblance to the classic NLS is also found to mediate nuclear import of proteins (25). In the present study, we have defined a unique NLS in RIP3, which does not share the preserved futures of classic NLS yet is able to mediate the nuclear import. Deletion experiments showed that there appears to be only a single NLS in RIP3, which is localized at its C terminus. In terms of its transporting ability, this unconventional NLS seems to be less powerful than NESs characterized in this study, because the net flow of RIP3 is normally from the nucleus to the cytosol, which is evidenced by strong cytoplasmic location of RIP3. To demonstrate that this NLS is sufficient to confer the nuclear import of full-length RIP3, we mutated NES-1 and NES-2 and deleted NES-3; the resultant RIP3 was found in the nucleus with dot-like fluorescence scattering in the cells. Due to drastic changes in their structures, it is not irrational to speculate that some proportion of RIP3 mutants could be located in cytoplasmic aggresomes (dot-like structures) before they are targeted to the proteasome for degradation. Nevertheless, the full characterization of these punctuate structures remains to be further investigated. Thus we conclude that this C-terminal NLS is truly responsible for the nuclear import of full-length RIP3. Nevertheless, we can not exclude the possibility that this sequence may bind some other cellular NLS-containing protein that is recognized by the nuclear import machinery.

We provide evidence for the first time that RIP3 is a nucleocytoplasmic shuttling protein. The nuclear export inhibitor LMB treatment results in nuclear translocation of RIP3, suggesting that RIP3 is capable of import to the nucleus by means of its C-terminal NLS and export to the cytoplasm through NES-1 and NES-2 by a CRM1-dependent mechanism. Additionally, the N-terminal NES-3 also contributes to the nuclear export of RIP3 in a CRM1-independent manner. RIP3, taken as a whole, is sensitive to LMB treatment, and it is therefore conceivable that a combination of NES-1 and NES-2 (both LMB-sensitive) appears to be stronger than NES-3 (LMB-insensitive). Our results suggest that the predominantly cytoplasmic distribution of RIP3 results from continuous nuclear import and powerful re-export. This novel shuttling ability of RIP3 may be the mechanism underlying the regulation of RIP3 for its biological functions.

It has been demonstrated that both RIP and RIP4 are involved in caspase-dependent processing during apoptosis (4, 26). RIP3 deletion mutants displaying nuclear localization exhibit profound pro-apoptotic activities that remind us to query whether RIP3 is processed during apoptotic induction. Although we have not yet confirmed its proteolytic cleavage site of RIP3 ectopically expressed in HeLa cells, Meylan et al. (4) claimed that RIP3 does undergo a similar processing to RIP.

In summary, we have identified novel and functional NLS and NESs in RIP3, which allow RIP3 to traffic as a nucleocytoplasmic shuttling protein. Significantly, RIP3 exhibits a considerable apoptosis-inducing activity in the nucleus. These findings will add to a growing list of death receptor-associated proteins such as TRADD and FADD that transport between the nucleus and cytoplasm.

	FOOTNOTES

 
^* This work was supported by the Key Project Fund (KSCX2-2-01-004) from the Chinese Academy of Sciences, by the National Natural Science Foundation of China (Grants 90208027, 30370308, and 30121001), and by a 973 Grant (2002CB713702) from the Ministry of Science and Technology of China. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed. Tel.: 86-551-360-7324; Fax: 86-551-360-6264; E-mail: wumian88{at}yahoo.com.

¹ The abbreviations used are: RIP, receptor-interacting protein; CRM1, chromosome region maintenance 1; aa, amino acid(s); DD, death domain; FADD, Fas-associated death domain; GFP, green fluorescent protein; LMB, leptomycin B; NES, nuclear export signal; NLS, nuclear localization signal; TNFR1, tumor necrosis factor receptor-1; TRADD, TNFR1-associated death domain; YFP, yellow fluorescent protein; MTS, mitochondrial targeting sequence; Z-VAD-Fmk, benzyloxycarbonyl-VAD-fluoromethyl ketone; PBS, phosphate-buffered saline; YFP₃, triple yellow fluorescent protein; PTD, protein transduction domain; mRIP, mouse RIP.

² Y. Yang, J. Ma, S. Feng, and M. Wu, unpublished data.

	ACKNOWLEDGMENTS

 
We are grateful to Drs. Minoru Yoshida for LMB and to Andrew Thorburn for the YFP₃ construct. We thank Dr. Tongchuan He for pEGFP-C1 and pCI-neo vectors. We also thank Drs. Xiaodong Wang and Yigong Shi for their constructive suggestion on Smac/DIABLO.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Yu, P. W., Huang, B. C. B., Shen, M., Quast, J., Chan, E., Xu, X., Nolan, G. P., Payan, D. G., and Luo, Y. (1999) Curr. Biol. 9, 539-542[CrossRef][Medline] [Order article via Infotrieve]
2. Sun, X. Q., Lee, J., Navas, T., Baldwin, D. T., Stewart, T. A., and Dixit, V. M. (1999) J. Biol. Chem. 274, 16871-16875[Abstract/Free Full Text]
3. Pazdernik, N. J., Donner, D. B., Goebl, M. G., and Harrington, M. A. (1999) Mol. Cell. Biol. 19, 6500-6508[Abstract/Free Full Text]
4. Meylan, E., Martinon, F., Thome, M., Gschwendt, M., and Tschopp, J. (2002) EMBO Rep. 3, 1201-1208[CrossRef][Medline] [Order article via Infotrieve]
5. Kasof, G. M., Prosser, J. C., Liu, D., Lorenzi, M. V., and Gomes, B. C. (2000) FEBS Lett. 473, 285-291[CrossRef][Medline] [Order article via Infotrieve]
6. Sun, X. Q., Yin, J. P., Starovasnik, M. A., Fairbrother, W. J., and Dixit, V. M. (2002) J. Biol. Chem. 277, 9505-9511[Abstract/Free Full Text]
7. Newton, K., Sun, X. Q., and Dixit, V. M. (2004) Mol. Cell. Biol. 24, 1464-1469[Abstract/Free Full Text]
8. Morgan, M., Thorburn, J., Pandolfi, P. P., and Thorburn, A. (2002) J. Cell Biol. 157, 975-984[Abstract/Free Full Text]
9. Gómez-Angelats, M., and Cidlowski, J. A. (2003) Cell Death Differ. 10, 791-797[CrossRef][Medline] [Order article via Infotrieve]
10. Screaton, R. A., Kiessling, S., Sansom, O. J., Millar, C. B., Maddison, K., Bird, A., Clarke, A. R., and Frisch, S. M. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 5211-5216[Abstract/Free Full Text]
11. Yang, Y. H., Ma, J., Song, Z. Y., and Wu, M. (2002) FEBS Lett. 532, 36-44[CrossRef][Medline] [Order article via Infotrieve]
12. Ke, N., Godzik, A., and Reed, J. C. (2001) J. Biol. Chem. 276, 12481-12484[Abstract/Free Full Text]
13. Song, Z. Y., Yao, X. B., and Wu, M. (2003) J. Biol. Chem. 278, 23130-23140[Abstract/Free Full Text]
14. Corpet, F. (1988) Nucleic Acids Res. 16, 10881-10890[Abstract/Free Full Text]
15. Kataoka, T., Holler, N., Micheau, O., Martinon, F., Tinel, A., Hofmann, K., and Tschopp, J. (2001) J. Biol. Chem. 276, 19548-19554[Abstract/Free Full Text]
16. Du, C. Y., Fang, M., Li, Y. C., Li, L., and Wang, X. D. (2000) Cell 102, 33-42[CrossRef][Medline] [Order article via Infotrieve]
17. Cour, T. I., Gupta, R., Rapacki, K., Skriver, K., Poulsen, F. M., and Brunak, S. (2003) Nucleic Acids Res. 31, 393-396[Abstract/Free Full Text]
18. Ura, S., Masuyama, N., Graves, J. D., and Gotoh, Y. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 10148-10153[Abstract/Free Full Text]
19. Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E. (1997) Nature 390, 308-311[CrossRef][Medline] [Order article via Infotrieve]
20. Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B., Yoshida, M., and Horinouchi, S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9112-9117[Abstract/Free Full Text]
21. Giannini, A., Mazor, M., Orme, M., Vivanco, M., Waxman, J., and Kypta, R. (2004) Exp. Cell Res. 295, 150-160[CrossRef][Medline] [Order article via Infotrieve]
22. Holaska, J. M., Black, B. E., Love, D. C., Hanover, J. A., Leszyk, J., and Paschal, B. M. (2001) J. Cell Biol. 152, 127-140[Abstract/Free Full Text]
23. Nigg, E. A. (1997) Nature 386, 779-787[CrossRef][Medline] [Order article via Infotrieve]
24. Jans, D. A., Xiao, C. Y., and Lam, M. H. C. (2000) BioEssays 22, 532-544[CrossRef][Medline] [Order article via Infotrieve]
25. Christophe, D., Christophe-Hobertus, C., and Pichon, B. (2000) Cell Signal. 12, 337-341[CrossRef][Medline] [Order article via Infotrieve]
26. Lin, Y., Devin, A., Rodriguez, Y., and Liu, Z. G. (1999) Gene Dev. 13, 2514-2526[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Smaldone and F. Ramirez Multiple pathways regulate intracellular shuttling of MoKA, a co-activator of transcription factor KLF7 Nucleic Acids Res., October 6, 2006; (2006) gkl659v3. [Abstract] [Full Text] [PDF]

				J. R. Hershfield, C. N. Madhavarao, J. R. Moffett, J. A. Benjamins, J. Y. Garbern, and A. Namboodiri Aspartoacylase is a regulated nuclear-cytoplasmic enzyme FASEB J, October 1, 2006; 20(12): 2139 - 2141. [Abstract] [Full Text] [PDF]

				A. Eulalio, I. Nunes-Correia, A. L. Carvalho, C. Faro, V. Citovsky, J. Salas, M. L. Salas, S. Simoes, and M. C. P. de Lima Nuclear Export of African Swine Fever Virus p37 Protein Occurs through Two Distinct Pathways and Is Mediated by Three Independent Signals J. Virol., February 1, 2006; 80(3): 1393 - 1404. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 279/37/38820    most recent M401663200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Y. Articles by Wu, M. Search for Related Content PubMed PubMed Citation Articles by Yang, Y. Articles by Wu, M. Social Bookmarking                      What's this?